tiprankstipranks
Advertisement
Advertisement

OGEN Stock Latest News

Oragenics begins Phase IIa dosing of concussion drug ONP-002 in Australia
Company AnnouncementsOragenics begins Phase IIa dosing of concussion drug ONP-002 in Australia
1d ago
OGEN
Oragenics Sets New 2025 Annual Shareholder Meeting Date
PremiumCompany Announcements
Oragenics Sets New 2025 Annual Shareholder Meeting Date
14d ago
8K
OGEN
Oragenics receives audit opinion with going concern explanation
PremiumThe Fly
Oragenics receives audit opinion with going concern explanation
20d ago
OGEN
Oragenics files annual report on Form 10-K
PremiumThe Fly
Oragenics files annual report on Form 10-K
28d ago
OGEN
Oragenics initiates Phase IIa clinical trial site activation
PremiumThe Fly
Oragenics initiates Phase IIa clinical trial site activation
1M ago
OGEN
Oragenics Advances Concussion Drug Trial and Explores CNS Asset Acquisitions
PremiumCompany AnnouncementsOragenics Advances Concussion Drug Trial and Explores CNS Asset Acquisitions
1M ago
OGEN
Oragenics explores potential acquisition of additional assets in CNS space
Premium
The Fly
Oragenics explores potential acquisition of additional assets in CNS space
1M ago
OGEN
Oragenics receives HREC approval for Phase IIa trial of ONP-002 in Australia
Premium
The Fly
Oragenics receives HREC approval for Phase IIa trial of ONP-002 in Australia
1M ago
OGEN
Oragenics previews targeted milestones for 2026
PremiumThe Fly
Oragenics previews targeted milestones for 2026
2M ago
OGEN
Oragenics partners with Duck Flats Pharma to support FDA IND trial design
PremiumThe Fly
Oragenics partners with Duck Flats Pharma to support FDA IND trial design
2M ago
OGEN
Oragenics Extends At-the-Market Equity Sales Agreement
PremiumCompany Announcements
Oragenics Extends At-the-Market Equity Sales Agreement
3M ago
8K
OGEN
Oragenics files $100M mixed securities shelf
PremiumThe Fly
Oragenics files $100M mixed securities shelf
3M ago
OGEN
Oragenics Adjusts Executive Compensation Plan
PremiumCompany AnnouncementsOragenics Adjusts Executive Compensation Plan
4M ago
8K
OGEN
Oragenics Regains NYSE Compliance After Public Offering
Premium
Company Announcements
Oragenics Regains NYSE Compliance After Public Offering
6M ago
8K
OGEN
Oragenics regains compliance with NYSE
Premium
The Fly
Oragenics regains compliance with NYSE
6M ago
OGEN
Oragenics, Receptor.AI partner to accelerate pipeline development
PremiumThe Fly
Oragenics, Receptor.AI partner to accelerate pipeline development
6M ago
OGEN
Oragenics Appoints Natasha Giordano to Board of Directors
PremiumCompany Announcements
Oragenics Appoints Natasha Giordano to Board of Directors
7M ago
8K
OGEN
Oragenics reports Q2 EPS ($3.10) vs. ($15.27) last year.
PremiumThe Fly
Oragenics reports Q2 EPS ($3.10) vs. ($15.27) last year.
8M ago
OGEN
Oragenics selects South Star Research as its CRO for ONP-002 Phase IIa trial
PremiumThe Fly
Oragenics selects South Star Research as its CRO for ONP-002 Phase IIa trial
9M ago
OGEN
Oragenics announces manufacturing agreement with Sterling Pharma for ONP-002
PremiumThe FlyOragenics announces manufacturing agreement with Sterling Pharma for ONP-002
9M ago
OGEN
Oragenics Raises $16.5M Through Public Offering
Premium
Company Announcements
Oragenics Raises $16.5M Through Public Offering
10M ago
8K
OGEN
Why Is Oragenics Stock (OGEN) Down 55% Today?
Premium
Market News
Why Is Oragenics Stock (OGEN) Down 55% Today?
10M ago
OGEN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >